Evaluating a brief intervention for asthma management in Black adults
Official title: BREATHE: An Efficacy-implementation Trial of a Brief Shared Decision Making Intervention Among Black Adults With Uncontrolled Asthma in Federally Qualified Health Centers (Trial and Post-trial)
Run by Columbia University · NCT05341726 · Data updated 2026-11-12
This study is testing a quick 9-minute asthma management approach called BREATHE to see if it helps Black adults with uncontrolled asthma feel better and manage their condition more effectively.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 400 (estimated) |
| Sponsor | Columbia University Academic / other |
| Drugs / interventions | Prednisone |
| Locations | 2 sites (Beacon, New York and 1 other locations) |
| Status | Recruiting |
| Started | January 19, 2023 |
| Main results expected | February 2028 |
| Study ends | February 2028 |
| Registry record updated | October 23, 2026 |
| Trial ID | NCT05341726 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are Black adults aged 18 and older with clinician-diagnosed persistent asthma who receive care at a partner FQHC.
✕Probably not a fit
Patients who are non-English speaking or have serious mental health conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This trial evaluates the efficacy of the BREATHE intervention, a 9-minute shared decision-making approach designed to improve asthma control among Black adults with uncontrolled asthma. The study will involve 200 participants receiving care at urban federally qualified health centers (FQHCs) and aims to identify barriers and facilitators to implementing this intervention widely. The BREATHE intervention is unique as it is integrated into routine office visits and delivered by the patient's own healthcare provider. Additionally, post-trial interviews will assess participant satisfaction and the acceptability of the intervention.
Why it matters
Potential benefit: If successful, this intervention could significantly improve asthma management and health outcomes for Black adults suffering from uncontrolled asthma.
How similar studies have gone: Previous pilot trials have shown success with similar interventions, indicating potential for positive outcomes in this study.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria (participants): Patients participants will 1. be adults (\> or = 18 years of age) 2. self-report race as 'Black' race (African American, African, Caribbean, West Indian, multi-racial \[Black AND one or more additional races\]); identify their ethnicity as Hispanic OR non-Hispanic 3. have clinician-diagnosed persistent asthma (defined as being prescribed inhaled corticosteroids in the last 48 months) or have had an asthma exacerbation (e.g., ER visit, course of Prednisone) regardless of controller medicine use 4. receive asthma care at a partner FQHC and 5. screen positive for uncontrolled asthma as measured by the Asthma Control Questionnaire- 6 items (ACQ-6) and erroneous beliefs as measured by the Conventional and Alternative Management for Asthma (CAM-A) survey. Exclusion Criteria (participants): 1. non-English speaking 2. serious mental health conditions that preclude completion of study procedures or confound analyses or 3. participation in a listening session Inclusion Criterion (clinicians): 1\. those who manage a panel of adult asthma patients Inclusion Criteria (loved ones): 1. must be identified by patient participant as a loved one and 2. loved one must be a family member or friend of the patient participant. Exclusion Criteria (loved ones): 1. non-English speaking or 2. serious mental health conditions that preclude completion of study procedures or confound analyses
Where it's running
-
Sun River Health
Beacon, New York, United States Recruiting -
Bedford Stuyvesant Family Health Center
Brooklyn, New York, United States Recruiting
Study contacts
- Principal investigator: Maureen George, PhD — Columbia University School of Nursing
- Study coordinator: Maureen George, PhD
- Email: mg3656@cumc.columbia.edu
- Phone: 2123051175
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Chronic Respiratory Disease Participant Engagement
This study tests whether adults with long-term lung conditions can get comfortable with a clinical trials unit and research team before joining future trials.
-
HB0056 in adults with moderate to severe asthma
This study tests HB0056 versus a placebo to see if it helps adults with moderate to severe asthma reduce rescue inhaler use and improve symptoms.
-
Tilrekimig (PF-07275315) for Severe Asthma: Aimed at Adults with Frequent Exacerbations
This study tests whether tilrekimig helps people with severe asthma who have had multiple flare-ups in the past year, by comparing it to a placebo given every four weeks.
-
Inhaled CHF10136 safety and pharmacokinetics in healthy adults and adults with asthma
This first-in-human study tests inhaled CHF10136 to see if it is safe and well tolerated, how it behaves in the body, and how it affects adults with asthma compared with placebo.
-
Biologics for Type 2 Inflammation in Asthma and COPD in Real World
This real-world study tests whether six biologic drugs can reduce flare-ups and improve symptoms in adults with asthma or COPD treated in routine care in China.
-
GSK5784283 vs placebo in uncontrolled asthma (PERSIST ASTHMA-2)
A new medicine called GSK5784283 is being tested to see if it lowers asthma flare-ups better than a placebo in people with uncontrolled asthma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.